Soleno Therapeutics launched an initiative in honor of Prader-Willi Syndrome, PWS, Awareness Day. The campaign aims to raise awareness of PWS and celebrate individuals living with this life-threatening disease. “At Soleno, we are deeply committed to making a meaningful difference in the lives of individuals with Prader-Willi syndrome,” said Dr. Anish Bhatnagar, Chief Executive Officer of Soleno Therapeutics. “This campaign aims to highlight the resilience and beauty within the PWS community, and we hope it will inspire greater awareness, understanding, and support for those living with this rare disease.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
- Soleno Therapeutics price target lowered to $59 from $65 at Oppenheimer
- Soleno Therapeutics management to meet with Piper Sandler
- Soleno Therapeutics reports Q1 EPS (59c), consensus (37c)
- Soleno Therapeutics initiated with an Outperform at Baird